health
Galderma IA and its consolidation in Colombian injectable aesthetics
Mauricio de Oliveira - Laura Posada Photo: Galderma
TL;DR
- Galderma IA has consistently strengthened its position in the Colombian injectable aesthetics market.
- Growth is attributed to business expansion, a solid portfolio, and a strategy focused on science, innovation, and medical professional development.
- The company meets increasing patient demand for minimally invasive treatments and improved skin quality.
- Galderma IA strengthens relationships with healthcare professionals, promoting safe practices and continuous scientific knowledge updates.
- The company's leadership is based on a product portfolio with clinical studies proving efficacy and safety, manufactured under strict international standards.
- Product approvals in major health-vigilant countries and by Invima in Colombia support the company's reliability.
- Current trends favor preventive, personalized solutions with natural results, emphasizing subtle procedures for skin texture, hydration, and luminosity.
- Innovation is central to Galderma IA's strategy, encompassing new technologies, scientific evidence generation, and ongoing support for healthcare professionals.
- Galderma IA impacts the medical community through structured educational programs and continuous updates via the GAIN network.
- GAIN promotes continuous education, scientific exchange, and networking among specialists, enhancing technical skills and evidence-based clinical decisions.
- The company's commitment to scientific evidence and safety is demonstrated by decades of research and millions of procedures performed globally.
- Galderma IA aims to further establish Colombia as a leading injectable aesthetics market in Latin America, fostering an integrated ecosystem and highly trained professionals.
- The company is committed to working with the medical community to promote responsible, science-based practices focused on patient well-being.